Effect of captopril and telmisartan on methotrexate-induced hepatotoxicity in rats: impact of oxidative stress, inflammation and apoptosis

Mina T. Kelleni, Salwa A. Ibrahim, Aly M. Abdelrahman

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Methotrexate (MTX) is a commonly used antineoplastic and anti-rheumatoid drug whose efficacy is limited by its hepatotoxicity. The aim of this study was to investigate the possible protective role of captopril (100 mg/kg/day, p.o. for seven days), an angiotensin converting enzyme inhibitor, and telmisartan (10 mg/kg/day p.o. for seven days), an angiotensin II receptor blocker with peroxisome proliferative receptor gamma (PPARγ) agonism, in a model of MTX (single dose 20 mg/kg i.p. at the fifth day) induced hepatotoxicity in rats. Results of the present study revealed MTX-induced hepatotoxicity as demonstrated by increased level of liver enzymes and confirmed by histopathology. Pretreatment with captopril or telmisartan produced a significant hepatic protection manifested as a significant (p < 0.05) decrease in serum levels of alanine transferase (ALT) and aspartate transferase (AST) and alkaline phosphatase (ALP) enzymes; hepatic malondialdehyde (MDA) and total nitrites and nitrates (NOx) levels; as well as a significant increase in hepatic superoxide dismutase (SOD) activity. In addition, there was a remarkable improvement in the histopathological features and a significant reduction in the expression of COX-2, iNOS and caspase-3 enzymes as compared with the MTX group. We recommend considering captopril/Telmisartan, if tolerated and not contraindicated, as preferable antihypertensive agents in patients receiving MTX in their chemotherapy protocols.

Original languageEnglish
Pages (from-to)371-377
Number of pages7
JournalToxicology Mechanisms and Methods
Volume26
Issue number5
DOIs
Publication statusPublished - Jun 12 2016

Fingerprint

Oxidative stress
Captopril
Methotrexate
Rats
Oxidative Stress
Apoptosis
Inflammation
Liver
Transferases
Enzymes
Peroxisomes
Chemotherapy
Angiotensin Receptor Antagonists
Nitrites
Malondialdehyde
Angiotensin-Converting Enzyme Inhibitors
Aspartic Acid
Caspase 3
Alanine
Antineoplastic Agents

Keywords

  • Captopril
  • hepatotoxicity
  • methotrexate
  • telmisartan

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

Effect of captopril and telmisartan on methotrexate-induced hepatotoxicity in rats : impact of oxidative stress, inflammation and apoptosis. / Kelleni, Mina T.; Ibrahim, Salwa A.; Abdelrahman, Aly M.

In: Toxicology Mechanisms and Methods, Vol. 26, No. 5, 12.06.2016, p. 371-377.

Research output: Contribution to journalArticle

@article{ce1b1ec712454a249cc5562180dc35b1,
title = "Effect of captopril and telmisartan on methotrexate-induced hepatotoxicity in rats: impact of oxidative stress, inflammation and apoptosis",
abstract = "Methotrexate (MTX) is a commonly used antineoplastic and anti-rheumatoid drug whose efficacy is limited by its hepatotoxicity. The aim of this study was to investigate the possible protective role of captopril (100 mg/kg/day, p.o. for seven days), an angiotensin converting enzyme inhibitor, and telmisartan (10 mg/kg/day p.o. for seven days), an angiotensin II receptor blocker with peroxisome proliferative receptor gamma (PPARγ) agonism, in a model of MTX (single dose 20 mg/kg i.p. at the fifth day) induced hepatotoxicity in rats. Results of the present study revealed MTX-induced hepatotoxicity as demonstrated by increased level of liver enzymes and confirmed by histopathology. Pretreatment with captopril or telmisartan produced a significant hepatic protection manifested as a significant (p < 0.05) decrease in serum levels of alanine transferase (ALT) and aspartate transferase (AST) and alkaline phosphatase (ALP) enzymes; hepatic malondialdehyde (MDA) and total nitrites and nitrates (NOx) levels; as well as a significant increase in hepatic superoxide dismutase (SOD) activity. In addition, there was a remarkable improvement in the histopathological features and a significant reduction in the expression of COX-2, iNOS and caspase-3 enzymes as compared with the MTX group. We recommend considering captopril/Telmisartan, if tolerated and not contraindicated, as preferable antihypertensive agents in patients receiving MTX in their chemotherapy protocols.",
keywords = "Captopril, hepatotoxicity, methotrexate, telmisartan",
author = "Kelleni, {Mina T.} and Ibrahim, {Salwa A.} and Abdelrahman, {Aly M.}",
year = "2016",
month = "6",
day = "12",
doi = "10.1080/15376516.2016.1191576",
language = "English",
volume = "26",
pages = "371--377",
journal = "Toxicology Mechanisms and Methods",
issn = "1537-6516",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Effect of captopril and telmisartan on methotrexate-induced hepatotoxicity in rats

T2 - impact of oxidative stress, inflammation and apoptosis

AU - Kelleni, Mina T.

AU - Ibrahim, Salwa A.

AU - Abdelrahman, Aly M.

PY - 2016/6/12

Y1 - 2016/6/12

N2 - Methotrexate (MTX) is a commonly used antineoplastic and anti-rheumatoid drug whose efficacy is limited by its hepatotoxicity. The aim of this study was to investigate the possible protective role of captopril (100 mg/kg/day, p.o. for seven days), an angiotensin converting enzyme inhibitor, and telmisartan (10 mg/kg/day p.o. for seven days), an angiotensin II receptor blocker with peroxisome proliferative receptor gamma (PPARγ) agonism, in a model of MTX (single dose 20 mg/kg i.p. at the fifth day) induced hepatotoxicity in rats. Results of the present study revealed MTX-induced hepatotoxicity as demonstrated by increased level of liver enzymes and confirmed by histopathology. Pretreatment with captopril or telmisartan produced a significant hepatic protection manifested as a significant (p < 0.05) decrease in serum levels of alanine transferase (ALT) and aspartate transferase (AST) and alkaline phosphatase (ALP) enzymes; hepatic malondialdehyde (MDA) and total nitrites and nitrates (NOx) levels; as well as a significant increase in hepatic superoxide dismutase (SOD) activity. In addition, there was a remarkable improvement in the histopathological features and a significant reduction in the expression of COX-2, iNOS and caspase-3 enzymes as compared with the MTX group. We recommend considering captopril/Telmisartan, if tolerated and not contraindicated, as preferable antihypertensive agents in patients receiving MTX in their chemotherapy protocols.

AB - Methotrexate (MTX) is a commonly used antineoplastic and anti-rheumatoid drug whose efficacy is limited by its hepatotoxicity. The aim of this study was to investigate the possible protective role of captopril (100 mg/kg/day, p.o. for seven days), an angiotensin converting enzyme inhibitor, and telmisartan (10 mg/kg/day p.o. for seven days), an angiotensin II receptor blocker with peroxisome proliferative receptor gamma (PPARγ) agonism, in a model of MTX (single dose 20 mg/kg i.p. at the fifth day) induced hepatotoxicity in rats. Results of the present study revealed MTX-induced hepatotoxicity as demonstrated by increased level of liver enzymes and confirmed by histopathology. Pretreatment with captopril or telmisartan produced a significant hepatic protection manifested as a significant (p < 0.05) decrease in serum levels of alanine transferase (ALT) and aspartate transferase (AST) and alkaline phosphatase (ALP) enzymes; hepatic malondialdehyde (MDA) and total nitrites and nitrates (NOx) levels; as well as a significant increase in hepatic superoxide dismutase (SOD) activity. In addition, there was a remarkable improvement in the histopathological features and a significant reduction in the expression of COX-2, iNOS and caspase-3 enzymes as compared with the MTX group. We recommend considering captopril/Telmisartan, if tolerated and not contraindicated, as preferable antihypertensive agents in patients receiving MTX in their chemotherapy protocols.

KW - Captopril

KW - hepatotoxicity

KW - methotrexate

KW - telmisartan

UR - http://www.scopus.com/inward/record.url?scp=84976264699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976264699&partnerID=8YFLogxK

U2 - 10.1080/15376516.2016.1191576

DO - 10.1080/15376516.2016.1191576

M3 - Article

C2 - 27269004

AN - SCOPUS:84976264699

VL - 26

SP - 371

EP - 377

JO - Toxicology Mechanisms and Methods

JF - Toxicology Mechanisms and Methods

SN - 1537-6516

IS - 5

ER -